A year after the killing sparked a wave of protest, Yale SOM leadership expert Jeffrey Sonnenfeld sees signs of a lasting change in corporate attitudes about racial justice.
Yale SOM’s Jeffrey Sonnenfeld and longtime UPS executive Teri Plummer McClure write that business leaders failed to live up to their pledge to defend democracy when they largely stood silent as Georgia enacted restrictions on voting.
We asked Yale SOM leadership expert Jeffrey Sonnenfeld, author of a landmark study of CEO succession, how Amazon will be changed by the departure of its founder.
In the wake of the presidential election, Yale SOM leadership expert Jeffrey Sonnenfeld hosted three urgent discussions with top CEOs, where they discussed their concern about attempts to overturn the results and made a much-reported pledge to freeze donations to legislators who voted to reject election results.
At a virtual meeting convened by Yale SOM leadership expert Jeffrey Sonnenfeld in the wake of the attack on the Capitol, CEOs voiced worries and brainstormed ideas for how business can help strengthen democracy.
In the final act of Donald Trump‘s presidency, Yale SOM's Jeffrey Sonnenfeld sees echoes of “monarchical” CEOs who purge truth-tellers and surround themselves with sycophants—and invariably make an involuntary exit from the C-suite.
In a hastily assembled call on November 6, corporate leaders agreed on the importance of smooth transition process and encouraged GOP leaders to endorse the integrity of the election.
As the U.S. approaches a divisive election, writes Yale SOM leadership expert Jeffrey Sonnenfeld, business leaders are calling for patience while ballots are counted and a peaceful transfer of power.
Yale SOM leadership expert Jeffrey Sonnenfeld, who studied a previous wave of diversity initiatives, describes how such well-intentioned initiatives can go awry—and how to get them back on track.
In the face of pressure from President Donald Trump, nine major pharmaceutical companies have signed a pledge to complete testing before submitting vaccines for approval. Yale's Jeffrey Sonnenfeld and Dr. Albert Ko write that the drugmakers’ caution may help provide badly needed confidence in the eventual vaccine.